SG10202108122YA - Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Info

Publication number: SG10202108122YA
Authority: SG; Singapore
Prior art keywords: peptides; cancers; combination; ovarian cancer; immunotherapy against
Prior art date: 2017-01-27

Application number

SG10202108122YA

Inventor

Heiko Schuster

Janet Peper

Kevin Röhle

Philipp Wagner

Hans-Georg Rammensee

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-27

Filing date

2018-01-26

Publication date

2021-09-29

2018-01-26 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2021-09-29 Publication of SG10202108122YA publication Critical patent/SG10202108122YA/en

Links

102000004196 processed proteins & peptides Human genes 0.000 title 2
108090000765 processed proteins & peptides Proteins 0.000 title 2
206010028980 Neoplasm Diseases 0.000 title 1
206010033128 Ovarian cancer Diseases 0.000 title 1
206010061535 Ovarian neoplasm Diseases 0.000 title 1
238000009169 immunotherapy Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001163—Phosphatases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Spectroscopy & Molecular Physics (AREA)
Medical Informatics (AREA)
Evolutionary Biology (AREA)
Bioinformatics & Computational Biology (AREA)

SG10202108122YA 2017-01-27 2018-01-26 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers SG10202108122YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762451255P	2017-01-27	2017-01-27
DE102017101671		2017-01-27

Publications (1)

Publication Number	Publication Date
SG10202108122YA true SG10202108122YA (en)	2021-09-29

Family

ID=61148200

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202108122YA SG10202108122YA (en)	2017-01-27	2018-01-26	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201906198PA SG11201906198PA (en)	2017-01-27	2018-01-26	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201906198PA SG11201906198PA (en)	2017-01-27	2018-01-26	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Country Status (23)

Country	Link
US (10)	US11248035B1 (en)
EP (2)	EP3573647B1 (en)
JP (2)	JP7337695B2 (en)
KR (2)	KR102699622B1 (en)
CN (1)	CN110198734A (en)
AU (6)	AU2018212584B2 (en)
BR (1)	BR112019015237A2 (en)
CA (1)	CA3048108A1 (en)
CL (8)	CL2019002093A1 (en)
CO (1)	CO2019008008A2 (en)
CR (4)	CR20210128A (en)
ES (1)	ES2946584T3 (en)
HR (1)	HRP20230512T8 (en)
IL (2)	IL299051A (en)
LT (1)	LT3573647T (en)
MX (1)	MX2019008843A (en)
NZ (1)	NZ754139A (en)
PE (1)	PE20191248A1 (en)
PH (1)	PH12019501377A1 (en)
RS (1)	RS64217B1 (en)
SG (2)	SG10202108122YA (en)
SI (1)	SI3573647T1 (en)
TW (1)	TW202325724A (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10738100B2 (en)	2017-01-27	2020-08-11	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202108122YA (en) *	2017-01-27	2021-09-29	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
DE102019114735A1 (en) *	2019-06-02	2020-12-03	PMCR GmbH	Class I and II HLA tumor antigen peptides for the treatment of breast cancer
US11528884B2 (en)	2019-08-28	2022-12-20	Dairycs Automatic Milking Ltd.	Dairy farm with a single or multiple frontal elevated roads
BR112022009087A2 (en) *	2019-11-11	2022-07-26	Ibi Ag Innovative Bio Insecticides Ltd	NANOBODY FOR INSECT CONTROL AND USES THEREOF
CN110838372B (en) *	2019-11-18	2022-07-12	武汉大学	A personalized cancer medication database system and its establishment method
CN111363744B (en) *	2020-02-26	2021-08-24	暨南大学	Berberine-mediated inhibition of UHRF1 gene and its use in the preparation of medicaments for the treatment of multiple myeloma
CN111735949B (en) *	2020-07-17	2023-07-21	北京信诺卫康科技有限公司	Combination of Wnt7a and CA125 as biomarkers and kits for early ovarian cancer
CN114107502A (en) *	2021-11-29	2022-03-01	四川大学华西医院	A diagnostic marker for upper urothelial carcinoma and its application
CN115948557B (en) *	2023-01-04	2025-09-02	陕西师范大学	Application of NLRP2 as a target in the diagnosis and/or treatment of ovarian cancer
CN116350787B (en) *	2023-03-15	2025-04-01	复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心)	Application of RBM15 inhibitors in paclitaxel chemotherapy resistance in ovarian cancer
CN117210561A (en) *	2023-05-09	2023-12-12	山东第一医科大学第一附属医院(山东省千佛山医院)	RNF106 application in esophageal squamous carcinoma detection, treatment and prognosis targets
CN116590263A (en) *	2023-07-02	2023-08-15	广州庆毅生物医药科技有限公司	Recombinant protein, monoclonal antibody, detection kit and application thereof
CN117233393B (en) *	2023-11-15	2024-02-09	四川大学华西医院	Double-immunohistochemical staining kit and application thereof in identifying benign and malignant bile duct epithelial tumors
CN118166098B (en) *	2024-02-05	2024-09-10	北京大学深圳医院	Application of reagent for detecting MAGEA4-AS1 in preparation of kit for diagnosing oral squamous cell carcinoma

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998009638A1 (en) *	1996-09-06	1998-03-12	The Brigham And Women's Hospital, Inc.	INHIBITION OF MAST CELL ACTIVATION BY gp49-BASED MECHANISMS AND REAGENTS
US6514935B1 (en) *	1997-03-14	2003-02-04	President And Fellows Of Harvard	Methods of treating hypertension
GB0017512D0 (en) *	2000-07-17	2000-08-30	Smithkline Beecham Biolog	Novel compounds
WO2003014151A2 (en) *	2001-08-10	2003-02-20	Genset S.A.	Human secreted proteins, their encoding polynucleotides, and uses thereof
AU2002324700A1 (en) *	2001-08-14	2003-03-03	Bayer Ag	Nucleic acid and amino acid sequences involved in pain
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
US20040142325A1 (en) *	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
CN1691964A (en) *	2002-09-06	2005-11-02	曼康公司	epitope sequence
US20070166318A1 (en) *	2003-05-30	2007-07-19	Macina Roberto A	Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
MXPA06005738A (en) *	2003-11-19	2006-12-14	Survac Aps	Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients.
RU2007135030A (en) *	2005-02-24	2009-03-27	Симайнз, Инк. (Us)	COMPOSITIONS AND METHODS FOR CLASSIFICATION OF BIOLOGICAL SAMPLES
PL1806358T3 (en)	2005-09-05	2010-08-31	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
CN106220721B (en) *	2007-03-26	2020-04-07	莱顿大学医学中心附属莱顿教学医院	PRAME derived peptides and immunogenic compositions comprising the same
UA103751C2 (en) *	2007-07-27	2013-11-25	Имматикс Биотекнолоджис Гмбх	Immunogenic peptide for immunotherapy
LT3320912T (en) *	2008-04-17	2021-07-12	Io Biotech Aps	INDOLAMINE 2,3-DIOXIGENASE-BASED IMMUNOTHERAPY
DE602008000891D1 (en)	2008-04-30	2010-05-12	Immatics Biotechnologies Gmbh	Novel formulations of tumor-associated peptides which bind to human leukocyte antigens of class I or II for vaccination
PT2119726E (en)	2008-05-14	2015-03-30	Immatics Biotechnologies Gmbh	Novel and powerful mhc-class ii peptides derived from survivin and neurocan
WO2010037397A1 (en) *	2008-10-01	2010-04-08	Dako Denmark A/S	Mhc multimers in cmv immune monitoring
EP2337795A2 (en) *	2008-10-01	2011-06-29	Dako Denmark A/S	Mhc multimers in cancer vaccines and immune monitoring
GB201006360D0 (en)	2010-04-16	2010-06-02	Immatics Biotechnologies Gmbh	Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012048291A2 (en)	2010-10-08	2012-04-12	Proteapex Therapeutics Llc	Compositions and methods for inhibition of mmp:mmp-substrate interactions
GB201315946D0 (en) *	2013-09-06	2013-10-23	Immune Targeting Systems Its Ltd	Oncology vaccine
GB201319446D0 (en) *	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201501017D0 (en) *	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) *	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202108122YA (en)	2017-01-27	2021-09-29	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US10738100B2 (en) *	2017-01-27	2020-08-11	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TW202028224A (en)	2018-09-17	2020-08-01	德商英麥提克生物技術股份有限公司	B*44 restricted peptides for use in immunotherapy against cancers and related methods

2018
- 2018-01-26 SG SG10202108122YA patent/SG10202108122YA/en unknown
- 2018-01-26 CR CR20210128A patent/CR20210128A/en unknown
- 2018-01-26 CN CN201880008006.XA patent/CN110198734A/en active Pending
- 2018-01-26 RS RS20230396A patent/RS64217B1/en unknown
- 2018-01-26 CR CR20190388A patent/CR20190388A/en unknown
- 2018-01-26 NZ NZ754139A patent/NZ754139A/en not_active IP Right Cessation
- 2018-01-26 IL IL299051A patent/IL299051A/en unknown
- 2018-01-26 SG SG11201906198PA patent/SG11201906198PA/en unknown
- 2018-01-26 CR CR20210130A patent/CR20210130A/en unknown
- 2018-01-26 SI SI201830920T patent/SI3573647T1/en unknown
- 2018-01-26 HR HRP20230512TT patent/HRP20230512T8/en unknown
- 2018-01-26 MX MX2019008843A patent/MX2019008843A/en unknown
- 2018-01-26 ES ES18702642T patent/ES2946584T3/en active Active
- 2018-01-26 EP EP18702642.2A patent/EP3573647B1/en active Active
- 2018-01-26 TW TW112105929A patent/TW202325724A/en unknown
- 2018-01-26 EP EP22151693.3A patent/EP4035675A3/en active Pending
- 2018-01-26 KR KR1020197022277A patent/KR102699622B1/en active Active
- 2018-01-26 CR CR20210129A patent/CR20210129A/en unknown
- 2018-01-26 BR BR112019015237A patent/BR112019015237A2/en not_active Application Discontinuation
- 2018-01-26 KR KR1020247028280A patent/KR20240134224A/en active Pending
- 2018-01-26 AU AU2018212584A patent/AU2018212584B2/en not_active Ceased
- 2018-01-26 CA CA3048108A patent/CA3048108A1/en active Pending
- 2018-01-26 LT LTEPPCT/EP2018/051952T patent/LT3573647T/en unknown
- 2018-01-26 PE PE2019001476A patent/PE20191248A1/en unknown
- 2018-01-26 JP JP2019539937A patent/JP7337695B2/en active Active
2019
- 2019-06-17 PH PH12019501377A patent/PH12019501377A1/en unknown
- 2019-07-25 IL IL268278A patent/IL268278B2/en unknown
- 2019-07-25 CO CONC2019/0008008A patent/CO2019008008A2/en unknown
- 2019-07-26 CL CL2019002093A patent/CL2019002093A1/en unknown
2020
- 2020-03-30 CL CL2020000817A patent/CL2020000817A1/en unknown
2021
- 2021-03-02 AU AU2021201349A patent/AU2021201349A1/en not_active Abandoned
- 2021-03-02 AU AU2021201347A patent/AU2021201347A1/en not_active Abandoned
- 2021-03-02 AU AU2021201348A patent/AU2021201348A1/en not_active Abandoned
- 2021-03-02 AU AU2021201350A patent/AU2021201350B9/en not_active Ceased
- 2021-03-02 AU AU2021201346A patent/AU2021201346A1/en not_active Abandoned
- 2021-06-11 US US17/345,211 patent/US11248035B1/en active Active
- 2021-06-17 US US17/350,964 patent/US11214608B2/en active Active
- 2021-06-17 US US17/350,879 patent/US11858978B2/en active Active
- 2021-09-02 US US17/465,426 patent/US12065477B2/en active Active
- 2021-09-02 US US17/465,381 patent/US11919940B2/en active Active
- 2021-09-02 US US17/465,460 patent/US11345737B1/en active Active
- 2021-09-22 CL CL2021002460A patent/CL2021002460A1/en unknown
- 2021-09-22 CL CL2021002459A patent/CL2021002459A1/en unknown
- 2021-09-22 CL CL2021002461A patent/CL2021002461A1/en unknown
2022
- 2022-10-21 CL CL2022002923A patent/CL2022002923A1/en unknown
- 2022-12-01 CL CL2022003406A patent/CL2022003406A1/en unknown
- 2022-12-01 CL CL2022003407A patent/CL2022003407A1/en unknown
2023
- 2023-03-30 US US18/192,743 patent/US20240034769A1/en active Pending
- 2023-03-30 US US18/192,752 patent/US20240076349A1/en active Pending
- 2023-04-07 US US18/297,069 patent/US20230312680A1/en active Pending
- 2023-04-07 US US18/297,064 patent/US20230365651A1/en active Pending
- 2023-08-23 JP JP2023135232A patent/JP2023179415A/en active Pending

Also Published As

Publication number	Publication date
KR20240134224A (en)	2024-09-06
AU2018212584A1 (en)	2019-06-20
US20230312680A1 (en)	2023-10-05
JP2020506690A (en)	2020-03-05
CR20210130A (en)	2021-03-31
AU2021201349A1 (en)	2021-03-18
NZ754139A (en)	2022-07-01
BR112019015237A2 (en)	2020-04-14
US20230002473A1 (en)	2023-01-05
CL2022003406A1 (en)	2023-05-26
CO2019008008A2 (en)	2019-10-21
US20220356227A1 (en)	2022-11-10
US12065477B2 (en)	2024-08-20
US20240034769A1 (en)	2024-02-01
HRP20230512T1 (en)	2023-08-04
US11248035B1 (en)	2022-02-15
IL299051A (en)	2023-02-01
JP7337695B2 (en)	2023-09-04
PH12019501377A1 (en)	2020-02-10
CL2021002461A1 (en)	2022-06-24
CR20210129A (en)	2021-03-26
TW202325724A (en)	2023-07-01
IL268278A (en)	2019-09-26
US11214608B2 (en)	2022-01-04
CR20210128A (en)	2021-04-26
US11858978B2 (en)	2024-01-02
US11919940B2 (en)	2024-03-05
EP3573647A1 (en)	2019-12-04
MX2019008843A (en)	2019-12-09
KR102699622B1 (en)	2024-08-28
HRP20230512T8 (en)	2023-09-15
RS64217B1 (en)	2023-06-30
AU2021201346A1 (en)	2021-03-18
AU2021201350B9 (en)	2024-02-22
CN110198734A (en)	2019-09-03
CL2021002460A1 (en)	2022-06-24
EP4035675A2 (en)	2022-08-03
SI3573647T1 (en)	2023-07-31
AU2021201348A1 (en)	2021-03-18
ES2946584T3 (en)	2023-07-21
IL268278B1 (en)	2023-01-01
CL2022002923A1 (en)	2023-04-14
AU2021201350A1 (en)	2021-03-18
AU2018212584B2 (en)	2020-12-10
KR20190112271A (en)	2019-10-04
JP2023179415A (en)	2023-12-19
US20240076349A1 (en)	2024-03-07
AU2021201350B2 (en)	2024-02-01
US11345737B1 (en)	2022-05-31
EP4035675A3 (en)	2022-11-16
CL2019002093A1 (en)	2019-11-29
CL2020000817A1 (en)	2020-10-16
LT3573647T (en)	2023-06-12
CL2022003407A1 (en)	2023-05-26
US20230365651A1 (en)	2023-11-16
US20230002474A1 (en)	2023-01-05
IL268278B2 (en)	2023-05-01
PE20191248A1 (en)	2019-09-18
EP3573647B1 (en)	2023-04-05
CL2021002459A1 (en)	2022-06-24
AU2021201347A1 (en)	2021-03-18
US20210340216A1 (en)	2021-11-04
SG11201906198PA (en)	2019-08-27
CR20190388A (en)	2019-10-16
CA3048108A1 (en)	2018-08-02

Publication	Publication Date	Title
IL268278A (en)	2019-09-26	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL256189A (en)	2018-02-28	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
ZA201800129B (en)	2018-12-19	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202001665QA (en)	2020-04-29	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL257331A (en)	2018-03-29	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL258599A (en)	2018-06-28	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201511792D0 (en)	2015-08-19	Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG11201706155XA (en)	2017-09-28	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202005950XA (en)	2020-07-29	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
ZA201707810B (en)	2018-11-28	Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
IL254081B (en)	2022-06-01	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
HK40103217A (en)	2024-06-28	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers